Engineered extrachromosomal oncogene amplifications promote tumorigenesis.
Davide Pradella, Minsi Zhang, Rui Gao, Melissa A. Yao, Katarzyna M. Gluchowska, Ylenia Cendon-Florez, Tanmay Mishra, Gaspare La Rocca, Moritz Weigl, Ziqi Jiao, Hieu H. M. Nguyen, Marta Lisi, Mateusz M. Ozimek, Chiara Mastroleo, Kevin Chen, Felix Grimm, Jens Luebeck, Shu Zhang, Andrea Alice Zolli,Eric G. Sun,Bhargavi Dameracharla,Zhengqiao Zhao,Yuri Pritykin, Carlie Sigel and Andrea Ventura
Nature (2024). https://doi.org/10.1038/s41586-024-08318-8
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.
Br J Cancer. 2024 Aug;131(3):601-610. doi: 10.1038/s41416-024-02760-1. Epub 2024 Jun 20.
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Oncogenic K-Ras suppresses global miRNA function.
Shui B, Beyett TS, Chen Z, Li X, La Rocca G, Gazlay WM, Eck MJ, Lau KS, Ventura A, Haigis KM.
Molecular Cell. 2023 Jul 20;83(14):2509-2523.e13. doi: 10.1016/j.molcel.2023.06.008. Epub 2023 Jul 3.
Interplay between K-RAS and miRNAs.
Shui B, La Rocca G, Ventura A, Haigis KM.
Trends Cancer. 2022 May;8(5):384-396. doi: 10.1016/j.trecan.2022.01.002. Epub 2022 Jan 31.PMID: 35093302
Inducible and reversible inhibition of miRNA-mediated gene repression in vivo.La Rocca G, King B, Shui B, Li X, Zhang M, Akat KM, Ogrodowski P, Mastroleo C, Chen K, Cavalieri V, Ma Y, Anelli V, Betel D, Vidigal J, Tuschl T, Meister G, Thompson CB, Lindsten T, Haigis K, Ventura A.
Elife. 2021 Aug 31;10:e70948. doi: 10.7554/eLife.70948.PMID: 34463618
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
Ciampricotti M, Karakousi T, Richards AL, Quintanal-Villalonga À, Karatza A, Caeser R, Costa EA, Allaj V, Manoj P, Spainhower KB, Kombak FE, Sanchez-Rivera FJ, Jaspers JE, Zavitsanou AM, Maddalo D, Ventura A, Rideout WM, Akama-Garren EH, Jacks T, Donoghue MTA, Sen T, Oliver TG, Poirier JT, Papagiannakopoulos T, Rudin CM.
Cancer Discov. 2021 Dec 1;11(12):3214-3229. doi: 10.1158/2159-8290.CD-21-0441.PMID: 34344693
The origins and consequences of UPF1 variants in pancreatic adenosquamous carcinoma.
Polaski JT, Udy DB, Escobar-Hoyos LF, Askan G, Leach SD, Ventura A, Kannan R, Bradley RK.
Elife. 2021 Jan 6;10:e62209. doi: 10.7554/eLife.62209.PMID: 33404013 Free
Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena, Srushti Kittane, Fan Wu, Yanyan Cai, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N Gorelick, Michael F. Berger, Ofra Novoplansky, Sankar Jagadeeshan, Yi Liao, Uwe Rix, Sandra Misale, Barry S Taylor, Alberto Bardelli, Jaclyn F Hechtman, David M Hyman, Moshe Elkabets, Elisa de Stanchina, Chandra S Verma, Andrea Ventura, Alexander Drilon and Maurizio Scaltriti
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
Cancer Discovery, October 1, 2020. doi: 10.1158/2159-8290.CD-20-0571
Luisa F. Escobar-Hoyos, Alex Penson, Ram Kannan, Hana Cho, Chun-Hao Pan, Rohit K. Singh, Lisa H. Apken, G. Aaron Hobbs, Renhe Luo, Nicolas Lecomte, Sruthi Babu, Fong Cheng Pan, Direna Alonso-Curbelo, John P. Morris IV, Gokce Askan, Olivera Grbovic-Huezo, Paul Ogrodowski, Jonathan Bermeo, Joseph Saglimbeni, Cristian D. Cruz, Yu-Jui Ho, Sharon A. Lawrence, Jerry P. Melchor, Grant A. Goda, Karen Bai, Alessandro Pastore. Simon J. Hogg. Srivatsan Raghavan, Peter Bailey, David K. Chang, Andrew Biankin, Kenneth R. Shroyer, Brian M. Wolpin. Andrew J. Aguirre, Andrea Ventura, Barry Taylor, Channing J. Der, Daniel Dominguez, Daniel Kümmel, Andrea Oeckinghaus, Scott W. Lowe, Robert K. Bradley , Omar Abdel-Wahab, Steven D. Leach
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Cancer Cell, June 18, 2020 DOI:https://doi.org/10.1016/j.ccell.2020.05.010
Ventura, A., and Dow, L. (2018) Modeling Cancer in the CRISPR Era. Annual Review of Cancer Biology Vol 2. Issue 1
Maddalo D, Ventura A. Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective. Cancer Res. 2016 Aug 12. [Epub ahead of print] Review. PubMed PMID: 27520450. [PMID: 27520450]
Li X, Wu R, Ventura A. The present and future of genome editing in cancer research. Hum Genet. 2016 Jul 18. [Epub ahead of print] Review. [PMID: 27432158]
Ventura A. NORAD: Defender of the Genome. Trends Genet. 2016 Jul;32(7):390-2. doi: 10.1016/j.tig.2016.04.002. Epub 2016 May 5. [PMID: 27157388]
Kannan R, Ventura A. The CRISPR revolution and its impact on cancer research. Swiss Med Wkly. 2015 Dec 10;145:w14230. doi: 10.4414/smw.2015.14230. eCollection 2015. PubMed PMID: 26661454. [PMID: 26661454]
Vidigal JA, Ventura A. Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. Nat Commun. 2015 Aug 17;6:8083. doi: 10.1038/ncomms9083.
Han YC, Vidigal JA, Mu P, Yao E, Singh I, González AJ, Concepcion CP, Bonetti C, Ogrodowski P, Carver B, Selleri L, Betel D, Leslie C, Ventura A. An allelic series of miR-17~92-mutant mice uncovers functional specialization and cooperation among members of a microRNA polycistron. Nat Genet. 2015 Jun 1. doi: 10.1038/ng.3321. [Epub ahead of print] [PMID: 26029871]
Fiori E, Babicola L, Andolina D, Coassin A, Pascucci T, Patella L, Han YC, Ventura A, Ventura R.Neurobehavioral Alterations in a Genetic Murine Model of Feingold Syndrome 2. Behav Genet. 2015 May 31. [Epub ahead of print] [PMID: 26026879]
La Rocca G, Olejniczak SH, González AJ, Briskin D, Vidigal JA, Spraggon L, DeMatteo RG, Radler MR, Lindsten T, Ventura A, Tuschl T, Leslie CS, Thompson CB. In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA. Proc Natl Acad Sci U S A. 2015 Jan 7. pii: 201424217. [Epub ahead of print] [PMID: 25568082]
Joana A. VIdigal and Andrea Ventura. The biological functions of miRNAs: lessons from in vivo studies. Trends in Cell Biology. 2014 Dec 4. [PMID:25484347]
Danilo Maddalo, Eusebio Manchado, Carla P. Concepcion, Ciro Bonetti, Joana A. Vidigal, Yoon-Chi Han, Paul Ogrodowski, Alessandra Crippa, Natasha Rekhtman, Elisa de Stanchina, Scott W. Lowe, and Andrea Ventura. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014 Oct 22. [PMID:25337876]
Frederique Zindy, Daisuke Kawauchi, Youngsoo Lee, Olivier Ayrault, Leila Ben Merzoug, Peter J. McKinnon, Andrea Ventura, and Martine F. Roussel. Role of the miR-17 approximately 92 cluster family in cerebellar and medulloblastoma development. Biol Open 3, 597-605 (2014). PMCID: PMC4154296 [PMID:24928431]]
Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D’Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A. Intact p53-Dependent Responses in miR-34-Deficient Mice. PLoS Genet. 2012 Jul; 8 (7) :e1002797. [PMID:22844244]
Alves Vidigal J, Ventura A. Embryonic stem cell miRNAs and their roles in development and disease. Semin Cancer Biol. 2012 May 4. [PMID:22561239]
Concepcion CP, Bonetti C, Ventura A. The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J. 2012 May-Jun; 18 (3) :262-7. [PMID:22647363]
Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID, Young KW, Ventura A, Concepcion CP, Han YC, Candi E, Knight RA, Mak TW, Melino G. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. Proc Natl Acad Sci U S A. 2011 Dec 27; 108 (52) :21099-104. [PMID:22160706]
Lal A, Thomas MP, Altschuler G, Navarro F, O’Day E, Li XL, Concepcion C, Han YC, Thiery J, Rajani DK, Deutsch A, Hofmann O, Ventura A, Hide W, Lieberman J. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011 Nov; 7 (11) :e1002363. [PMID:22102825]
de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, Van Haeringen A, Geneviève D, Goldenberg A, Oufadem M, Manouvrier S, Munnich A, Vidigal JA, Vekemans M, Lyonnet S, Henrion-Caude A, Ventura A, Amiel J. Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans. Nat Genet. 2011 Sep 4; 43 (10) :1026-30. [PMID:21892160]
Sage J, Ventura A. miR than meets the eye. Genes Dev. 2011 Aug 15; 25 (16) :1663-7. [PMID:21852531]
Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC, Lai EC. Widespread regulatory activity of vertebrate microRNA* species. RNA. 2011 Feb; 17 (2) :312-26. [PMID:21177881]
Yao E, Ventura A. A new role for miR-182 in DNA repair. Mol Cell. 2011 Jan 21; 41 (2) :135-7. [PMID:21255724]
Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D’Andrea A, Sander C, Ventura A. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009 Dec 15; 23 (24) :2806-11. [PMID:20008931]
Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009 Feb 20; 136 (4) :586-91. [PMID:19239879]
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008 Mar 7; 132 (5) :875-86. [PMID:18329372]
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007 Feb 8; 445 (7128) :661-5. [PMID:17251932]